Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for Newly Diagnosed Anaplastic Oligodendroglioma
NCT00400816Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Aug 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in anaplastic oligodendroglioma (AO) and oligoastrocytoma (OA), sponsored by Cleveland Clinic. Primary endpoint: Progression-Free Survival. Started Aug 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytoma (OA)
Beyond the preview
Go deeper on NCT00400816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400816.